BIO Quote, Trading Chart, Bio-Rad Laboratories Inc. Class A
$625.67 Last:
0.46% Change Percent:
$626 Open:
$625.67 Previous Close:
$627.32 High:
$616.9 Low:
81,847 Volume:
06/21/2021 04:43:57 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
BIO Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-21 | 626 | 625.67 | 627.32 | 616.9 | 81,847 |
| 2021-06-18 | 616.01 | 622.8 | 626.62 | 616.01 | 168,882 |
| 2021-06-17 | 611.26 | 617.6 | 619 | 607.94 | 115,580 |
| 2021-06-16 | 610.52 | 612.26 | 615.75 | 608.84 | 154,168 |
| 2021-06-15 | 608.76 | 609.27 | 610.98 | 602.96 | 98,658 |
| 2021-06-14 | 602.97 | 606.67 | 607 | 598.31 | 146,043 |
| 2021-06-11 | 605.92 | 601.68 | 605.92 | 598.3 | 95,713 |
| 2021-06-10 | 580.5 | 602.97 | 606.6778 | 577.85 | 257,881 |
| 2021-06-09 | 585.18 | 581.16 | 586.31 | 578.55 | 300,109 |
| 2021-06-08 | 584 | 581.66 | 584 | 575 | 154,864 |
| 2021-06-07 | 578.66 | 579.58 | 583.37 | 577.75 | 157,333 |
| 2021-06-04 | 582.97 | 581.28 | 584.25 | 575.02 | 160,025 |
| 2021-06-03 | 576.4 | 581.59 | 584.295 | 575 | 125,014 |
| 2021-06-02 | 580 | 581.32 | 584.6 | 576.74 | 118,088 |
| 2021-06-01 | 603.37 | 581.46 | 607.11 | 581.195 | 164,936 |
| 2021-05-31 | 603.66 | 602.37 | 610 | 601.71 | 102,518 |
| 2021-05-28 | 603.66 | 602.37 | 610 | 601.71 | 102,508 |
| 2021-05-27 | 593.46 | 598.57 | 600.81 | 591.01 | 191,422 |
| 2021-05-26 | 590.9 | 591.57 | 592.06 | 580.01 | 131,972 |
| 2021-05-25 | 592.74 | 592.93 | 596.02 | 584.89 | 146,326 |
Bio-Rad Laboratories Inc. Class A Company Name:
BIO Stock Symbol:
NYSE Market:
News, Short Squeeze, Breakout and More Instantly...
-
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its PREvalence ™ ddPCR ® SARS-CoV-2 Wastewater Quantification Kit, a sensitive, accurate, and cost-effective ...
-
Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board PR Newswire SHANGHAI , June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic ...
-
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC PR Newswire CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China , June ...